ENOV · Enovis CORP
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 5, 2022; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Enovis reported Q2 sales of $583M (5% organic), 14% underlying adjusted EPS growth to $0.90, and 70bps underlying adjusted EBITDA margin expansion to 17.9%, while reaffirming full-year 2026 guidance despite $10M of incremental inflationary headwinds and softer Western Europe and Middle East markets.
- + Recon grew 8% reported / 6% organic in Q2 with U.S. hips and knees up 8%, and Arvis moved into full U.S. commercial launch with strong early surgeon feedback.
- + Adjusted gross margin expanded ~120bps underlying to 62% and adjusted EBITDA margin improved 70bps underlying to 17.9%, with management calling out a multi-year cadence of margin expansion.
- + Adjusted EPS of $0.90 represented 14% underlying growth in Q2 and 12% earnings growth through the first half.
- + Company reaffirmed full-year 2026 guidance for revenue ($2.31-2.37B, 4-6% organic), adjusted EBITDA ($425-435M), adjusted EPS ($3.52-$3.73), and >25% free cash flow conversion.
- − Q2 growth faced a ~100bps headwind from the Middle East conflict and softer Western European markets (France, Spain, Italy), with management guiding to a more seasonally soft Q3 than in prior years.
- − Full-year 2026 will absorb approximately $10M of incremental inflationary pressure from raw materials, freight and distribution costs tied to the Middle East conflict, offsetting the $8M tariff refund benefit.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENOV
this stock
Enovis CORP
|
$1.07B | -30.3% | +6.7% | — | 15.1% |
|
ABT
Abbott Laboratories
|
$188.69B | -13.5% | +5.7% | 30.3 | 1.2% |
|
MDT
Medtronic plc
|
$120.46B | -2.0% | +8.4% | 23.2 | 1.1% |
|
SYK
Stryker Corp
|
$116.27B | -13.8% | +11.2% | 31.4 | 1.8% |
|
BSX
Boston Scientific Corp
|
$69.27B | -49.9% | +12.5% | 19.4 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 5, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENOV | -25.5% | -30.3% | -20.0% | -24.5% | -30.3% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -25.6% | -29.9% | -35.2% | -24.9% | -43.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.